|
|
Post by georgethenight2 on Nov 2, 2022 5:15:58 GMT -5
All we need to hear. These words were from Michael Benkowitz, President and Chief Operating Officer of United Therapeutics.
“Tyvaso DPI has provided a catalyst to our growth trajectory and has us well positioned to achieve our goal of 6,000 patients on Tyvaso by the end of the year.”
|
|
|
|
Post by neil36 on Nov 2, 2022 6:26:12 GMT -5
UTHR's cost of product sales increased from $26.8 million to $37.1 million quarter over quarter.
"Cost of product sales, excluding share-based compensation. Cost of product sales for the three months ended September 30, 2022 increased as compared to the same period in 2021, primarily due to an increase in royalty expense and product costs due to an overall increase in sales."
|
|
|
|
Post by akemp3000 on Nov 2, 2022 7:05:11 GMT -5
Excellent news. Does this mean we'll learn the definition of low double-digit royalties next week? Possibly not. It could be on a sliding scale that starts out a little high then reduces over time with higher volume?
|
|
|
|
Post by lex8955 on Nov 2, 2022 7:28:40 GMT -5
Let’s just be grateful for UTHR as they pulled MNKD and all us investors from going bankrupt. Thrilled to hear these results!!
|
|
|
|
Post by derekewhitlock on Nov 2, 2022 8:38:05 GMT -5
At, approximately, minute 35 of UTHR presentation Martine just stated that Tyvaso DPI is the "star of the show" when answering a question about near term future revenues. Enjoy your day ladies and gents
|
|
|
|
Post by sayhey24 on Nov 2, 2022 8:58:58 GMT -5
At, approximately, minute 35 of UTHR presentation Martine just stated that Tyvaso DPI is the "star of the show" when answering a question about near term future revenues. Enjoy your day ladies and gents It seems MNKD pps went positive on that news. |
|
|
|
Post by caesar on Nov 2, 2022 9:04:44 GMT -5
Did anyone pick up on what Martine's comment on Nintedanib was?
|
|
|
|
Post by boomboom on Nov 2, 2022 13:34:59 GMT -5
Very cool! Also very cool on the "star of the show" comment. That, hopefully, says a lot.
Do we know approx how many patients were on Tyvaso before DPI was released? I am wondering that if we assume 6000 by year end are we then able to interpolate and estimate the gap between the scripts we are seeing reported from Symphony and what they really are? This would need to make the assumption that all new patients are coming on with DPI and not nebulize which I think should be somewhat safe to assume?
|
|
|
|
Post by bthomas55ep on Nov 2, 2022 13:49:17 GMT -5
Very cool! Also very cool on the "star of the show" comment. That, hopefully, says a lot. Do we know approx how many patients were on Tyvaso before DPI was released? I am wondering that if we assume 6000 by year end are we then able to interpolate and estimate the gap between the scripts we are seeing reported from Symphony and what they really are? This would need to make the assumption that all new patients are coming on with DPI and not nebulize which I think should be somewhat safe to assume? It seems like the 6000 by year end meant the existing Tyvaso patients, that included all the new ones being added to DPI. Not 6000 new DPI patients. I could be wrong |
|
|
|
Post by neil36 on Nov 2, 2022 15:13:26 GMT -5
So $257 million in Tyvaso revenue to UTHR in a quarter divided by thirteen weeks equals just under $20 million a week.
If half of that consists of Tyvaso DPI, that would represent $10 million a week. At the lowest possible double-digit royalty, that would represent a million dollars a week to MNKD or $52 million a year, and that is not counting future growth or manufacturing costs plus.
I'm trying to get my head around how the market could possibly see today's report as a negative for MNKD, other than the fact that IBB and much off the market had a late-day sell-off. UTHR, on the other hand, held on to most of its impressive gains.
I'm thinking we have much brighter days ahead.
|
|
|
|
DPI news.
Nov 2, 2022 15:25:59 GMT -5
via mobile
Post by cjm18 on Nov 2, 2022 15:25:59 GMT -5
So $257 million in Tyvaso revenue to UTHR in a quarter divided by thirteen weeks equals just under $20 million a week. If half of that consists of Tyvaso DPI, that would represent $10 million a week. At the lowest possible double-digit royalty, that would represent a million dollars a week to MNKD or $52 million a year, and that is not counting future growth or manufacturing costs plus. I'm trying to get my head around how the market could possibly see today's report as a negative for MNKD, other than the fact that IBB and much off the market had a late-day sell-off. UTHR, on the other hand, held on to most of its impressive gains. I'm thinking we have much brighter days ahead. If half consists of tyvaso dpi…. Did anyone on the call talk about the conversion rate? 50% might be the long term number but investors look out 6 months. The symphony data is flat recently. |
|
|
|
Post by robbmo on Nov 2, 2022 15:36:04 GMT -5
So $257 million in Tyvaso revenue to UTHR in a quarter divided by thirteen weeks equals just under $20 million a week. If half of that consists of Tyvaso DPI, that would represent $10 million a week. At the lowest possible double-digit royalty, that would represent a million dollars a week to MNKD or $52 million a year, and that is not counting future growth or manufacturing costs plus. I'm trying to get my head around how the market could possibly see today's report as a negative for MNKD, other than the fact that IBB and much off the market had a late-day sell-off. UTHR, on the other hand, held on to most of its impressive gains. I'm thinking we have much brighter days ahead. If half consists of tyvaso dpi…. Did anyone on the call talk about the conversion rate? 50% might be the long term number but investors look out 6 months. The symphony data is flat recently. They said all new conversions were about 50/50, and doctors were not reaching out to existing patients to transition them, but waiting until they came in on their next appointment. This was expected behavior for existing patient transitions. |
|
|
|
Post by casualinvestor on Nov 2, 2022 15:44:35 GMT -5
Tyvaso revenue from earnings statements:
2020 Q4 - $131M
2021 Q4 - $167M
2022 Q1 - $172M
2022 Q2 - $201M
2022 Q3 - $257M
To guess, I'd say that gains in Q2 and Q3 provide a lowball estimate of DPI sales, including conversions. That's $83M. Gross sales to net is a 50% haircut or a little more. So maybe $5-6M in royalties for Q3? I'm not sure we ever knew what % of revenue manufacturing cost was. Anyone?
|
|
|
|
Post by robbmo on Nov 2, 2022 15:55:04 GMT -5
Tyvaso revenue from earnings statements: 2020 Q4 - $131M 2021 Q4 - $167M 2022 Q1 - $172M 2022 Q2 - $201M 2022 Q3 - $257M To guess, I'd say that gains in Q2 and Q3 provide a lowball estimate of DPI sales, including conversions. That's $83M. Gross sales to net is a 50% haircut or a little more. So maybe $5-6M in royalties for Q3? I'm not sure we ever knew what % of revenue manufacturing cost was. Anyone? There is also the revenue from distribution. I am not sure how meaningful it is, but Mike has made a point of distinguishing it from manufacturing in a few presentations now, so I would guess it adds some value. |
|
|
|
Post by Clement on Nov 2, 2022 16:13:29 GMT -5
Tyvaso revenue from earnings statements: 2020 Q4 - $131M 2021 Q4 - $167M 2022 Q1 - $172M 2022 Q2 - $201M 2022 Q3 - $257M To guess, I'd say that gains in Q2 and Q3 provide a lowball estimate of DPI sales, including conversions. That's $83M. Gross sales to net is a 50% haircut or a little more. So maybe $5-6M in royalties for Q3? I'm not sure we ever knew what % of revenue manufacturing cost was. Anyone? Those quarterly numbers are net ..... not gross. See page 20 of the 10Q for Q3. d18rn0p25nwr6d.cloudfront.net/CIK-0001082554/5deaefa3-5c8c-4336-9fa4-4c7da8c53f06.pdf |
|
